NCT04664933 Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With Endovascular Therapy (INSIST-ET)
| NCT ID | NCT04664933 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hui-Sheng Chen |
| Condition | Stroke, Ischemic |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2020-12-01 |
| Primary Completion | 2026-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2020-12-01 with a primary completion date of 2026-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To explore the safety and feasibility of intra-arterial neuroprotective strategy in acute ischemic stroke patients who received recanalization operation.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥18 years; 2. Acute ischemic stroke patients who is eligible for endovascular treatment; 3. Signed informed consent. Exclusion Criteria: 1. Modified Rankin Score \>2 caused by a history of prior stroke; 2. Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia (\<80000/mm3); 3. Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis; 4. Severe hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure over 110 mmHg); 5. Unsuitable for this clinical studies assessed by researcher.
Frequently Asked Questions
Who can join the NCT04664933 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke, Ischemic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04664933 currently recruiting?
Yes, NCT04664933 is actively recruiting participants. Visit ClinicalTrials.gov or contact Hui-Sheng Chen to inquire about joining.
Where is the NCT04664933 trial being conducted?
This trial is being conducted at Shenyang, China.
Who is sponsoring the NCT04664933 clinical trial?
NCT04664933 is sponsored by Hui-Sheng Chen. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.